MMSC vs FAB: Distinct and Unrelated Medical Entities
MMSC (methylmalonic acidemia, cobalamin C type) and FAB (French-American-British classification) are completely different medical concepts that should not be compared—MMSC refers to a specific inherited metabolic disorder, while FAB is a morphology-based classification system for hematologic malignancies.
Understanding Each Entity
FAB Classification System
The French-American-British (FAB) classification is a morphology-based system dating from 1976 that categorizes acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) based on blast cell appearance under light microscopy using cytochemical stains 1.
Key FAB characteristics:
- Requires ≥30% blast cells in bone marrow or peripheral blood for AML diagnosis 2, 1
- Uses Wright or Wright-Giemsa staining with assessment of malignant cell lines 1
- Applicable only to untreated patients (chemotherapy alters morphology) 1
- Classifies MDS into subtypes: RA, RARS, RAEB, RAEB-T, and CMML 3
Critical limitation: FAB has been largely superseded by the WHO classification system, which is now the gold standard 1, 4. The WHO classification (first edition 2001, revised 2016) incorporates genetic features, immunophenotype data, and clinical information—not just morphology 1. The WHO lowered the blast threshold to 20% and recognizes that certain cytogenetic abnormalities [t(8;21), t(15;17), inv(16)] establish AML diagnosis regardless of blast percentage 2, 1, 5.
MMSC (Cobalamin C Deficiency)
MMSC, more accurately termed cblC deficiency or cobalamin C disease, is an autosomal recessive inherited metabolic disorder caused by biallelic pathogenic variants in the MMACHC gene 6, 7, 8. This is the most common inborn error of cobalamin (vitamin B12) metabolism 9, 7.
Clinical manifestations include:
- Multisystem involvement: neurological dysfunction (microcephaly, seizures, developmental delay, ataxia), hematologic abnormalities, renal disease (thrombotic microangiopathy), cardiovascular complications 9, 8
- Biochemical hallmarks: elevated methylmalonic acid and homocysteine 6, 10
- Can present from neonatal period to adulthood 6, 10
- Life-threatening complications: aortic dissection, pulmonary arterial hypertension, acute kidney injury 6, 8
Treatment approach:
- High-dose hydroxocobalamin (vitamin B12) is the mainstay therapy 7, 11
- Adjunctive therapy: betaine, levocarnitine, folic acid 7, 8
- Long-term hydroxocobalamin is well-tolerated even at higher doses with prolonged treatment 11
- Early diagnosis and treatment initiation are critical for outcomes 9, 7
Why This Comparison is Inappropriate
These are fundamentally different medical concepts:
- FAB = A classification methodology for categorizing blood cancers
- MMSC/cblC = A specific genetic metabolic disease entity
The only potential source of confusion might be that both involve hematologic abnormalities, but they operate in completely different diagnostic and therapeutic frameworks. A patient with cblC deficiency may have anemia or other blood abnormalities 9, but these would not be classified using FAB criteria, which specifically applies to myeloid malignancies.
If you are encountering these terms together in a clinical context, clarify whether:
- You're asking about MDS (myelodysplastic syndrome) vs FAB classification
- You're asking about a patient with cblC deficiency who has concurrent hematologic findings
- There's been a terminology mix-up in documentation